Clinical Trial Update: Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104 [Phase 1]

View source ↗

Summary

Phase 1 study of FR104 (intravenous) in rheumatoid arthritis and transplant complications assessing safety, tolerability, PK/PD, and immunogenicity after single…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis
• Transplant Rejection

Drugs mentioned

• FR104

Snippet

Sponsor: OSE Immunotherapeutics | Conditions: Rheumatoid Arthritis, Complication of Transplant | Phase 1 | Status: COMPLETED